Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study
Mayen-Chacón, Ana-Lucía; Sabra, Mirna; Aglago, Elom-K; Perlemuter, Gabriel; Voican, Cosmin; Ramos, Inés; Debras, Charlotte; Blanco, Jessica; Viallon, Vivian; Ferrari, Pietro; Olsen, Anja; Tjonneland, Anne; Langmann, Fie; Dahm, Christina-C; Rothwell, Joseph-A; Laouali, Nasser; Marqués, Chloe; Schulze, Matthias-B; Katzke, Verena-A; Kaaks, Rudolf; Palli, Domenico; Macciotta, Alessandra; Panico, Salvatore; Tumino, Rosario; Agnoli, Claudia; Farras, Marta; Molina-Montes, Esther; Amiano, Pilar; Chirlaque-López, María-Dolores; Castilla, Jesús; Werner, Marten; Boden, Stina; Heath, Alicia-K; Tsilidis, Kostas; Aune, Dagfinn; Weiderpass, Elisabete; Freisling, Heinz; Gunter, Marc-J; Jenab, Mazda
Fecha:
2024-06
Resumen:
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS) are implicated in the aetiology of non-communicable diseases. Our study aimed to evaluate associations between NAFLD and MetS with overall and cause-specific mortality. METHODS: We used dietary, lifestyle, anthropometric and metabolic biomarker data from a random subsample of 15,784 EPIC cohort participants. NAFLD was assessed using the fatty liver index (FLI) and MetS using the revised definition. Indices for metabolic dysfunction-associated fatty liver disease (MAFLD) were calculated. The individual associations of these indices with overall and cause-specific mortality were assessed using multivariable Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (95%CIs). As a subobjective, risk associations with adaptations of new classifications of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic and alcohol-related liver disease (MetALD) were also assessed. RESULTS: Among the 15,784 sub-cohort participants, a total of 1997 deaths occurred (835 due to cancer, 520 to CVD, 642 to other causes) over a median 15.6 (IQR, 12.3-17.1) years of follow-up. Compared to an FLI < 30, FLI ? 60 was associated with increased risks of overall mortality (HR = 1.44, 95%CI = 1.27-1.63), and deaths from cancer (HR = 1.32, 95%CI = 1.09-1.60), CVD (HR = 2.06, 95% CI = 1.61-2.63) or other causes (HR = 1.21, 95%CI = 0.97-1.51). Mortality risk associations were also elevated for individuals with MAFLD compared to those without. Individuals with MetS were at increased risk of all mortality endpoints, except cancer-specific mortality. MASLD and MetALD were associated with higher risk of overall mortality. CONCLUSIONS: Our findings based on a prospective cohort suggest that individuals with hepatic steatosis or metabolic dysfunction have a higher overall and cause-specific mortality risk.
Mostrar el registro completo del ítem